Coty (NYSE:COTY) & Niagen Bioscience (NASDAQ:NAGE) Head to Head Review

Coty (NYSE:COTY – Get Free Report) and Niagen Bioscience (NASDAQ:NAGE – Get Free Report) are both consumer staples companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Risk & Volatility

Coty has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Valuation and Earnings

This table compares Coty and Niagen Bioscience”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coty $5.81 billion 0.60 -$604.80 million ($0.65) -6.07
Niagen Bioscience $129.42 million 1.13 $17.38 million $0.12 15.33

Niagen Bioscience has lower revenue, but higher earnings than Coty. Coty is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

42.4% of Coty shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 0.5% of Coty shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Coty and Niagen Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coty -9.74% 7.11% 2.28%
Niagen Bioscience 8.37% 10.18% 7.57%

Analyst Recommendations

This is a summary of recent recommendations for Coty and Niagen Bioscience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coty 2 10 1 0 1.92
Niagen Bioscience 0 1 4 1 3.00

Coty currently has a consensus price target of $3.48, suggesting a potential downside of 11.72%. Niagen Bioscience has a consensus price target of $8.50, suggesting a potential upside of 361.96%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Coty.

Summary

Niagen Bioscience beats Coty on 13 of the 15 factors compared between the two stocks.

About Coty

(Get Free Report)

Coty is a global beauty company that develops, manufactures, markets and distributes fragrances, cosmetics, skin care and body-care products. Its portfolio spans prestige and consumer beauty, with products sold in markets around the world. The company’s brands include CoverGirl, Rimmel London, Max Factor and Sally Hansen. Coty also produces fragrances and beauty products under license for a range of fashion and lifestyle brands. Founded in Paris in 1904 by perfumer François Coty, the company has grown from a fragrance business into a broad-based beauty group.

About Niagen Bioscience

(Get Free Report)

Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.

Receive News & Ratings for Coty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coty and related companies with MarketBeat.com's FREE daily email newsletter.